ARC Journal of Cancer Science Volume 8, Issue 1, 2023, PP 1-6 ISSN (Online): 2455-6009 https://doi.org/10.20431/2455-6009.0801001 www.arcjournals.org ARC Journal of Cancer Science Page | 1 Prostate Cancer and Immune Evasion Mechanisms Radoslav N. Ivanov, Soren Hayrabedyan, Krassimira Todorova* Laboratory of Reproductive OMICs Technologies, Institute of Biology and Immunology of Reproduction "Acad. Kiril Bratanov", Bulgarian Academy of Sciences 1. INTRODUCTION More than 1,414,259 new instances of prostate cancer (PCa) are diagnosed annually and more than 375,304 deaths are attributed to PCa globally in 2020 GLOBOCAN[1]. Many predetermined elements are involved in initiating prostate cancer, including genetic predisposition, inflammation, and enhanced cell proliferation. Lesions arise when these processes emerge in the normally functioning prostate epithelium, setting off a chain reaction that may either lead straight to primary PCa or proliferative inflammatory atrophy (PIA) or create an intermediate stage known as prostate intraepithelial neoplasia (PIN), which boosts the activity of luminal secretory cells. Many variables, including age, race, genetics, employment, and infectious agents, estrogenic hormones in dietary carcinogens, have been linked to prostate cancer recurrence, as shown by molecular and pathological analyses of human prostate carcinoma samples and research using animal models of PCa. [2] [3] Epithelial ducts and acinuses are organised in a fibromuscular stromal network of fibroblastic and myofibroblastic cells to form the human prostate, a glandular organ lying below the bladder (Figure 1A). The epithelium is composed of one layer of colonial secretory luminal cells and two layers of closely related basal cells that comprise stem cells, transit- enhancing (TA) cells, and basally engaged (CB) cells.[4] [5] Glandular epithelium is made up of two basic cell types: secretory luminal cells and basal epithelial cells. Both prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) are released into semen by a kind of cell called a luminal cell. What exactly basal cells are supposed to do remains a mystery. They function as a pool of progenitors that can Abstract: Prosteroid cancer is a global health issue, with 1,414,259 new instances diagnosed annually and 375,304 deaths attributed to PCa globally in 2020. It is caused by genetic predisposition, inflammation, and enhanced cell proliferation. The human prostate is composed of two basic cell types: secretory luminal cells and basal epithelial cells. Lesions arise when these processes emerge in the normally functioning prostate epithelium, setting off a chain reaction that may either lead to primary PCa or proliferative inflammatory atrophy (PIA) or create an intermediate stage known as prostate intraepithelial neoplasia (PIN). Hormonal replacement helps the gland bounce back just as rapidly, while estrogenic hormones in dietary carcinogens have been linked to prostate cancer recurrence. As basal cells are not postmitotic, glandular renewal must be caused by the proliferation of surviving basal cells. Prostate adenocarcinoma is a significant clinical challenge, with 2.5 million patients worldwide surviving after being diagnosed with this type of cancer. It is based on the finding that the cytokeratin subtype composition of tumor cells always matches that of luminal cells and never that of basal cells. Cancer cells produce PSA and PAP, and have a unique phenotype known as epithelial transition in immune-like cells. The British National Cancer Institute (NHI) defines cancer survival as "the physical, psychosocial, and economic problems of cancer from diagnosis to death." After treatment for prostate cancer, most men report psychosexual difficulties. This is especially true for men over the age of 50. Prostate cancer is able to actively suppress anti-tumor immune responses due to the expression of immune cell molecules (such as heterogeneous cytokines and their receptors, transcription factors regulating immune cells signaling, Ig motifs, and immune checkpoint molecules). Keywords: prostate cancer, immune evasion, signaling *Corresponding Author: Krassimira Todorova, Laboratory of Reproductive OMICs Technologies, Institute of Biology and Immunology of Reproduction "Acad. Kiril Bratanov", Bulgarian Academy of Sciences. ktodorova@ibir.bas.bg